You are here

What’s the Stem Cells Buzz this Week? – pNSC Brain Repair, Pluripotent stem cell‐derived Osteoblasts, Chemokine Treatment for ISD, and Adverse Events in Adipose-Derived Cell Therapy!



The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Primitive Neural Stem Cells Repair the Mouse Brain

Adult mouse primitive neural stem cells (pNSCs) derived from the forebrain subependymal zone bordering the lateral ventricles usually reside in a very slow-cycling state; however, researchers from the lab of Rachel L. Reeve (University of Toronto, Canada) hypothesized that GFAP-OCT4+ pNSCs could play a key role in brain repair. Their new STEM CELLS study now demonstrates that pNSCs proliferate and contribute to the replacement of definitive NSCs (developmentally downstream of pNSCs) following cytosine β-d-arabinofuranoside ablation. Could pNSCs represent an excellent source of cells for cell-based regenerative therapies in humans?

Pluripotent stem cell‐derived Osteoblasts Get the Job Done!

Osteoblasts are a crucial cell type, given that they support hematopoiesis in the bone marrow and maintain healthy bone. Now, researchers from the lab of Joy Y. Wu (Stanford University School of Medicine, USA) have assessed whether pluripotent stem cells can rescue aberrant skeletal development and bone marrow hematopoiesis in vivo. In their new STEM CELLS study, Chubb et al. describe two novel complementation assays, which demonstrate that induced pluripotent stem cell‐derived osteoblasts can compensate for the loss of osteoblast lineage cells in transgenic mice to form mineralized bone and bone marrow hematopoietic niche in vivo.


Chemokine vs. Stem Cells: Which is best for Urinary Sphincter Deficiency Treatment?

Intrinsic urinary sphincter deficiency (ISD) treatment normally comprises skeletal muscle precursor cell (skMPC) therapy; however, results have proved disappointing. A new STEM CELLS Translational Medicine article from the lab of J. Koudy Williams (Wake Forest University, Winston-Salem, North Carolina, USA) now compares the safety and efficacy of the cell homing chemokine CXCL12 versus skMPCs in a rat model of ISD. William et al. demonstrate that CXCL12 treatment can restore sphincter muscle content with little clinical or tissue pathology in the short term. Therefore, treatment with a chemical that stimulates the body to heal itself may represent a novel ISD treatment strategy.

Reviewing Reported Adverse Events in Adipose-Derived Cell Therapy

A new review article from the lab of Navid Mohamadpour Toyserkani (Odense University Hospital, Odense, Denmark) aims to bring us all up to date with adverse reactions associated with adipose-derived cell therapy with a special focus on the risk of thromboembolic, immunological, and oncological safety concerns. Toyserkani et al. suggest that while adipose-derived cell therapy has a favorable safety profile, improvements to safety assessment are required to fully appreciate all adverse events moving forward. See STEM CELLS Translational Medicine now for a great read!

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!